UCB Ventures and Alphabet unit GV took part in the RNA-targeting gene therapy developer's first publicly disclosed funding round, which was led by Arch Venture Partners.
US-based biotherapeutics developer Locana secured $55m on Wednesday in a series A round that included subsidiaries of internet technology conglomerate Alphabet and biopharmaceutical company UCB.
Venture capital firm Arch Venture Partners led the round, investing alongside Singaporean government-owned investment firm Temasek and VC firm Lightstone Ventures. Alphabet and UCB participated through their GV and UCB Ventures subsidiaries respectively.
Founded in 2016, Locana is developing RNA-targeting gene therapies designed to target diseases caused by mutations in the patient’s DNA.
The company…
